Analysts think these blue chips are top buys for investors right now. But why? The post 2 of the highest-quality blue chip ...

If, like Warren Buffett, you’re struggling to find deals in this market, then here are some ASX shares our Foolish writers ...

CSL Seqirus is one of three healthcare businesses owned by the parent company. The other two are CSL Behring, focused on biotherapies and rare diseases, and CSL Vifor, focused on iron deficiency and ...

From office conversions to co-living, housing providers are delivering unique ways to deliver much needed housing supply in coveted urban areas.

CSL Ltd ( ASX: CSL) shares have faced a tough year. Whilst the broader market has extended to new highs in 2024, shares in ...

The Behring plasma arm should also achieve margin ... but the company manages to winkle outgrowth in the mid to long term. CSL shares were down 0.65 per cent to $290.10 in an overall bouncier ...

(RTTNews) - At the Annual General Meeting, Paul McKenzie, Chief Executive Officer of CSL Ltd. (CSL.AX), reaffirmed the company's financial guidance for fiscal year 2025. The company still expects ...

Blood products and vaccines giant CSL (ASX:CSL) has reaffirmed current-year earnings expectations as it enters a period of ...

Carlisle Companies Inc (NYSE:CSL) achieved record third-quarter results in both EBITDA margin and earnings per share, despite challenges in the residential market and weather-related disruptions.

It operates through the CSL Behring and Seqirus segments. The CSL Behring segment provides plasma therapies and conducts early stage research on plasma and non plasma therapies. The Seqirus ...